<DOC>
	<DOCNO>NCT00509678</DOCNO>
	<brief_summary>The purpose study help determine effectiveness rituxan ( without methotrexate ) treatment psoriatic arthritis .</brief_summary>
	<brief_title>Rituxan With Without Methotrexate Psoriatic Arthritis</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy rituximab , without methotrexate , joint , enthesium skin psoriatic arthritis patient inadequate response methotrexate either tried anti-TNF therapy inadequate fail response anti-TNF therapy . To explore biologic mechanism action via histological immunohistochemical evaluation pre post treatment biopsy psoriatic plaque .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Active disease least 6 month duration . Receiving treatment outpatient basis . The patient least one evaluable skin plaque , 2 cm diameter , follow target lesion score ( scalp groin lesion use ) . Presence PsA per CASPAR category : Psoriasis , Nail Changes , Negative RF test , Dactylitis radiological evidence juxtaarticular new bone formation . Subjects great equal 3 tender ( 68 joint ) 3 swollen ( 66 ) joint screen baseline . History malignancy resolve squamous basal cell cervical carcinoma Presence significant medical illness , opinion investigator , would potentially compromise subject 's ability participate trial Presence another rheumatic skin disease , opinion investigator , could confound ability discern response History presence HIV History severe allergic anaphylactic reaction humanize murine monoclonal antibody History recurrent significant infection history recurrent bacterial infection Known active bacterial , viral , fungal , mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antibiotic within 4 week screen oral antibiotic within 2 week prior screen . History psychiatric disorder , judgment investigator , would make patient inappropriate entry trial would lead poor compliance . Concurrent treatment DMARD ( except MTX ) , antiTNF alpha therapy biologic therapy . Topical medication treat psoriasis limited class VI VII low potency steroid palm , sol foot , axilla groin . Concurrent treatment DMARD ( except MTX ) , antiTNF alpha therapy biologic therapy . Topical medication treat psoriasis limited class VI VII low potency steroid palm , sol foot , axilla groin . Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) . Previous treatment celldepleting therapy , include investigational agent ( e.g. , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 ) . Previous treatment within 6 month i.v . gammaglobulin , Orencia , toclizumab , natalizumab Prosorba Column . Intraarticular parental corticosteroid injection within 4 week prior screen . Previous treatment rituximab ( MabThera/Rituxan ) Immunization vaccine within 4 week prior randomization ( e.g . ; MMR , Varivax , Smallpox ) . One intraarticular steroid joint injection allow , affect joint exclude assessment thereafter . Subjects take analgesic within 12 hour prior joint assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Arthritis</keyword>
</DOC>